Cadrenal Therapeutics, Inc. Common Stock (CVKD)
US — Healthcare Sector
Automate Your Wheel Strategy on CVKD
With Tiblio's Option Bot, you can configure your own wheel strategy including CVKD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVKD
- Rev/Share 0.0011
- Book/Share 2.1915
- PB 5.6811
- Debt/Equity 0.0
- CurrentRatio 3.5558
- ROIC -3.3498
- MktCap 25483332.0
- FreeCF/Share -5.9506
- PFCF -2.1831
- PE -2.3392
- Debt/Assets 0.0
- DivYield 0
- ROE -1.964
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CVKD
Published: August 11, 2025 by: Business Wire
Sentiment: Neutral
Published: August 11, 2025 by: Business Wire
Sentiment: Neutral
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.
Read More
About Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- IPO Date 2023-01-20
- Website https://www.cadrenal.com
- Industry Biotechnology
- CEO Quang X. Pham
- Employees 4
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.